摘要
目的:初步探讨解脲脲原体生物群构成比与临床症状的相关性。方法:收集并登记性病门诊就诊人群的Uu临床标本,以多条带抗原(multiple-banded antigen,MB-Ag)基因为靶位,设计分群引物,进行分群检测。结果:170株Uu中,parvo生物群占64.71%(110/170),T960生物群占34.12%(58/170),两群都检测到的比例为1.17%(2/170)。不同临床症状女性患者中parvo及T960生物群所占比率差异有统计学意义(P<0.05)。结论:parvo生物群可能是Uu中的优势菌群,T960生物群可能更容易引起临床相关症状或体征。
Objective：To investigate the ratio of biovariants of Ureaplasma urealyticum（Uu） and the relationship with clinical symptom. Methods：A total of 170 patients who visited the STD clinic were enrolled in the study and the clinical isolates were biotyped by polymerase chain reaction（PCR） to determine the variants of the multiple-banded antigen（MB-Ag） gene. Results：Out of the 170 strains of Uu,parvo is 64.71%（110/170）,T960 is 34.12%（58/170） and the presence of both variants are 1.17%（2/170）.There was significant difference in the ratio of biovariants of Ureaplasma urealyticum of the female patients with different clinical symptoms（P0.05）. Conclusion：It is possible that Parvo is the dominant biovariant,while T960 may be the biovariant that tends to cause related symptoms in the lower genital tract.
出处
《皮肤性病诊疗学杂志》
2011年第1期16-18,共3页
Journal of Diagnosis and Therapy on Dermato-venereology
关键词
解脲脲原体
生物群
临床症状
Ureaplasma urealyticum（Uu）
Biovars
Clinical symptom
